- Home
- FHN vs BBIO Comparison
FHN vs BBIO Comparison
Compare FHN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- BBIO
- Stock Information
- Founded
- FHN 1864
- BBIO 2015
- Country
- FHN United States
- BBIO United States
- Employees
- FHN N/A
- BBIO N/A
- Industry
- FHN Major Banks
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- BBIO Health Care
- Exchange
- FHN Nasdaq
- BBIO Nasdaq
- Market Cap
- FHN 10.7B
- BBIO 8.8B
- IPO Year
- FHN N/A
- BBIO 2019
- Fundamental
- Price
- FHN $21.88
- BBIO $47.08
- Analyst Decision
- FHN Buy
- BBIO Strong Buy
- Analyst Count
- FHN 17
- BBIO 16
- Target Price
- FHN $23.26
- BBIO $61.50
- AVG Volume (30 Days)
- FHN 8.3M
- BBIO 2.2M
- Earning Date
- FHN 07-16-2025
- BBIO 08-05-2025
- Dividend Yield
- FHN 2.74%
- BBIO N/A
- EPS Growth
- FHN 28.03
- BBIO N/A
- EPS
- FHN 1.55
- BBIO N/A
- Revenue
- FHN $3,081,000,000.00
- BBIO $127,415,000.00
- Revenue This Year
- FHN $11.02
- BBIO $106.33
- Revenue Next Year
- FHN $3.61
- BBIO $54.30
- P/E Ratio
- FHN $14.17
- BBIO N/A
- Revenue Growth
- FHN 4.55
- BBIO N/A
- 52 Week Low
- FHN $14.34
- BBIO $21.72
- 52 Week High
- FHN $23.00
- BBIO $48.68
- Technical
- Relative Strength Index (RSI)
- FHN 51.72
- BBIO 63.26
- Support Level
- FHN $21.87
- BBIO $45.11
- Resistance Level
- FHN $23.00
- BBIO $47.11
- Average True Range (ATR)
- FHN 0.57
- BBIO 1.33
- MACD
- FHN -0.10
- BBIO -0.28
- Stochastic Oscillator
- FHN 36.89
- BBIO 51.58
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.